Springer Nature
13395_2019_198_MOESM1_ESM.tif (2.33 MB)

Additional file 1: of Preclinical rationale for entinostat in embryonal rhabdomyosarcoma

Download (2.33 MB)
posted on 2019-05-21, 05:00 authored by Narendra Bharathy, Noah Berlow, Eric Wang, Jinu Abraham, Teagan Settelmeyer, Jody Hooper, Matthew Svalina, Zia Bajwa, Martin Goros, Brian Hernandez, Johannes Wolff, Ranadip Pal, Angela Davies, Arya Ashok, Darnell Bushby, Maria Mancini, Christopher Noakes, Neal Goodwin, Peter Ordentlich, James Keck, Douglas Hawkins, Erin Rudzinski, Atiya Mansoor, Theodore Perkins, Christopher Vakoc, Joel Michalek, Charles Keller
Figure S1. Phosphohistone H3 (pHH3) expression and rhabdomyoblast count in VCR and ENT + VCR-treated eRMS. (a) pHH3 expression of eRMS mouse tumor (animal id: 67833) after treatment with single agent VCR. Scale Bar: 50 μM. (b) pHH3 expression of eRMS mouse tumor (animal id: 67822) after treatment with both ENT and VCR. Scale bar: 50 μM (c) Histological scoring of various mouse eRMS after four different types of treatment; DMSO, VCR, ENT, or a combination of ENT and VCR (ENT + VCR). Counted all fields 500 to 3000 cells under low and higher magnification on each slide. This count excluded endothelial cells and inflammatory cells. * denotes not determined while ** denotes myoglobin was immunohistochemically positive. (TIF 2381 kb)


National Institute of Health (US)